Microbiome - Competitive Landscape, Technology & Pipeline Analysis 2017 - Comprehensive Insights About Pipeline Drugs Across This Class - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Microbiome - Competitive Landscape, Technology and Pipeline Analysis - 2017" drug pipelines to their offering.

The report provides comprehensive insights about pipeline drugs across this class. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Microbiome.

This report provides information on the therapeutic development based on the Microbiome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the company's information involved in the therapeutic development of the products.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope of the Report:

  • Overview of the global Microbiome pipeline scenario, products and associated companies information.
  • Coverage of global Microbiome therapies under development.
  • Competitive landscape of products for key players and related indications.
  • Coverage of licensors, collaborators and development partners, deal terms and deal values estimation.
  • Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities.
  • Highlights of licensing & collaboration opportunities and funding details.
  • Highlights of latest Microbiome technologies.
  • Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis.

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/3b5d42/microbiome

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biopharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biopharmaceuticals